GlassScriptPhysician profile
Nikhil Banerjee
NPI 1932424850
$32,316.73
in general payments reported to CMS, 2019-2025
42 companies · $20K in 2025
The $20K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,530 · 2020: $1,400 · 2021: $1,448 · 2022: $1,610 · 2023: $2,249 · 2024: $4,087 · 2025: $20K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,875 · Consulting Fee: $8,676 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,020 · Travel and Lodging: $1,645 · Education: $112.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,874.64 |
| Consulting Fee | $8,676.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,020.00 |
| Travel and Lodging | $1,645.09 |
| Education | $112.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $10,871.66 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $6,365.81 | 2024-2025 | Voquezna |
| Abbvie INC. | $3,960.03 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,017.80 | 2019-2025 | Tremfya, Stelara, Remicade |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,224.22 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Medtronic, INC. | $1,192.02 | 2023-2025 | Interstim, Gi Genius |
| Pfizer INC. | $1,128.54 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $765.51 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Qol Medical, LLC | $482.45 | 2019-2025 | Sucraid |
| Celgene Corporation | $437.42 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $436.04 | 2024-2025 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $290.98 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $285.39 | 2024-2025 | Vowst |
| Regeneron Healthcare Solutions, INC. | $255.11 | 2022-2025 | Dupixent |
| Amgen INC. | $244.73 | 2020-2025 | Avsola, Amjevita, Uplizna |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $239.51 | 2019-2023 | Rebyota |
| Ucb, INC. | $218.62 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $198.52 | 2019-2024 | |
| Gilead Sciences, INC. | $184.29 | 2024-2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $182.48 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $164.34 | 2019-2024 | |
| Redhill Biopharma INC. | $144.96 | 2020-2023 | Movantik, Talicia, Aemcolo |
| Allergan, INC. | $127.93 | 2019 | |
| Romark Laboratories, Lc | $116.43 | 2019-2020 | |
| Organon LLC | $88.03 | 2023-2024 | Renflexis, Hadlima |
| Braintree Laboratories, INC. | $87.62 | 2019-2023 | Sutab |
| Ardelyx, INC. | $85.13 | 2022-2024 | Ibsrela |
| Alnylam Pharmaceuticals INC. | $70.84 | 2023-2025 | Givlaari |
| Conmed Corporation | $59.53 | 2022-2024 | Conmed Dilation, Conmed Polypectomy |
| Sandoz INC. | $54.83 | 2023-2024 | Hyrimoz |
| Boston Scientific Corporation | $43.73 | 2024 | Spyglass |
| E.R. Squibb & Sons, L.L.C. | $43.49 | 2022 | |
| Nestle Healthcare Nutrition INC. | $43.24 | 2023 | |
| Micro-Tech Endoscopy USA, INC. | $38.90 | 2025 | Cold Snares, Buttons |
| Celltrion USA INC. | $36.60 | 2024-2025 | Zymfentra, Vegzelma |
| Alfasigma USA, INC. | $34.31 | 2020 | |
| Shionogi INC | $30.97 | 2019 | |
| Novo Nordisk INC | $19.74 | 2025 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.86 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $14.35 | 2024 | Andexxa |
| Mauna Kea Technologies, INC. | $11.77 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$22,836.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nikhil Banerjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.